



Dr. Stefan Bilz

Endokrinologie | Diabetologie | Osteologie | Stoffwechselerkrankungen · Dept.
I

Kontakt

Dr. Stefan Bilz
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T 071 494 1228
stefan.bilz@kssg.ch

Homepage

www.endocrinology.ch

Bereiche

Endokrinologie | Diabetologie | Osteologie | Stoffwechselerkrankungen

Publikationen (59)

Bösch M, Baty F, Bilz S, Brutsche M, Rassouli F. Tracking Real-World Physical Activity in Chronic Obstructive Pulmonary Disease Over One Year: Results from a Monocentric, Prospective, Observational Cohort Study. *Int J Chron Obstruct Pulmon Dis* 2024; 19:1921-1929.

Brenner R, Drescher T, Locher R, Bilz S, Rickli H, Brändle M, Nobel D, Weilenmann D, Ammann P, Maeder M. Pulmonary and Systemic Hemodynamics in Patients with Hyperthyroidism. *Am J Med* 2023

Dehos B, Bilz S. [Lipid Management in Practice]. *Praxis (Bern 1994)* 2023; 112:649-654.

Singeisen H, Renström F, Laimer M, Lehmann R, Bilz S, Brändle M. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care—a SwissDiab study. *Eur J Prev Cardiol* 2023; 30:1473-1481.

Jensen A, Renström F, Aczel S, Folie P, Biraima M, Beuschlein F, Bilz S. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. *Obes Surg* 2023:1-9.

Zanchi A, Jehle A, Lamine F, Vogt B, Czerlau C, Bilz S, Seeger H, de Seigneux S. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. *Swiss Med Wkly* 2023; 153:40004.

Baumgartner A, Olpe T, Griot S, Mentil N, Staub N, Burn F, Schindera S, Kaegi-Braun N, Tribolet P, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Müller-Stich B, Schuetz P. Association of CT-based diagnosis of sarcopenia with prognosis and treatment response in patients at risk of malnutrition - A secondary analysis of the Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) trial. *Clin Nutr* 2022; 42:199-207.

Eugster P, Brown N, Hubers S, Schütze I, Reul A, Nölting S, Beuschlein F, Sigrist S, Bilz S, Kolb W, Henzen C, Fischli S, Trepp R, Wuerzner G, Matter M, Abid K, Vocat C, Maurer J, Grouzmann E. Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. *Clin Chim Acta* 2022; 534:146-155.

Stalder L, Kaegi-Braun N, Gressies C, Gregoriano C, Tribolet P, Lobo D, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Prospective validation of five malnutrition screening and assessment instruments among medical inpatients: Secondary analysis of a randomized clinical trial. *Clin Nutr* 2022; 41:1307-1315.

Kaegi-Braun N, Boesiger F, Tribolet P, Gomes F, Kutz A, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Lobo D, Cederholm T, Mueller B, Schuetz P. Validation of modified GLIM criteria to predict adverse clinical outcome and response to nutritional treatment: A secondary analysis of a randomized clinical trial. *Clin Nutr* 2022; 41:795-804.

Bretschera C, Boesiger F, Kaegi-Braun N, Hersberger L, Lobo D, Evans D, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Admission serum albumin concentrations and response to nutritional therapy in hospitalised patients at malnutrition risk: Secondary analysis of a randomised clinical trial. *EClinicalMedicine* 2022; 45:101301.

Nanchen D, Reichert N, Rossi M, Crljenica C, Mueller C, Mach F, Koskinas K, Rickli H, Bilz S, Carballo D, Sudano I. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. *Adv Ther* 2021; 39:504-517.

Kaegi-Braun N, Tribolet P, Baumgartner A, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Hoess C, Pavlicek V, Schmid S, Bilz S, Sigrist S, Brändle M, Benz C, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Value of handgrip strength to predict clinical outcomes and therapeutic response in malnourished medical inpatients: Secondary analysis of a randomized controlled trial. *Am J Clin Nutr* 2021; 114:731-740.

Hersberger L, Dietz A, Bürgler H, Bargetzi A, Bargetzi L, Kägi-Braun N, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure. *J Am Coll Cardiol* 2021; 77:2307-2319.

Baumgartner A, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Sigrist S, Bilz S, Pavlicek V, Pachnis D, Parra L, Hersberger L, Bargetzi A, Bargetzi L, Kaegi-Braun N, Tribolet P, Gomes F, Hoess C, Schuetz P. The impact of nutritional support on malnourished inpatients with aging-related vulnerability. *Nutrition* 2021; 89:111279.

Walter A, Baty F, Rassouli F, Bilz S, Brutsche M. Diagnostic precision and identification of rare diseases is dependent on distance of residence relative to tertiary medical facilities. *Orphanet J Rare Dis* 2021; 16:131.

Bargetzi A, Emmenegger N, Wildisen S, Nickler M, Bargetzi L, Hersberger L, Segerer S, Kaegi-Braun N, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Admission kidney function is a strong predictor for the response to nutritional support in patients at nutritional risk. *Clin Nutr* 2021; 40:2762-2771.

Baumgartner A, Hasenboehler F, Cantone J, Hersberger L, Bargetzi A, Bargetzi L, Kaegi-Braun N, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Effect of nutritional support in patients with lower respiratory tract infection: Secondary analysis of a randomized clinical trial. *Clin Nutr* 2020; 40:1843-1850.

Kaegi-Braun N, Brändle M, Benz C, Henzen C, Mattmann S, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Sigrist S, Bilz S, Tribolet P, Gomes F, Fehr R, Baechli V, Geiser M, Deiss M, Kutz A, Bregenzer T, Hoess C, Pavlicek V, Schmid S, Schuetz P. Six-month outcomes after individualized nutritional support during the hospital stay in medical patients at nutritional risk: Secondary analysis of a prospective randomized trial. *Clin Nutr* 2020

Schoeb M, Räss A, Frei N, Aczel S, Brändle M, Bilz S. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study. *Obes Surg* 2020; 30:2659-2666.

Merker M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Brändle M, Sigrist S, Bilz S, Felder M, Gueissaz L, Bolliger R, Tribolet P, Kägi-Braun N, Gomes F, Hoess C, Pavlicek V, Schuetz P. Association of Baseline Inflammation With Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open* 2020; 3:e200663.

Hersberger L, Brändle M, Benz C, Henzen C, Nigg M, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Sigrist S, Bilz S, Schmid S, Bargetzi L, Bargetzi A, Tribolet P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Kägi-Braun N, Hoess C, Pavlicek V, Schuetz P. Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial. *Clin Nutr* 2019; 39:2720-2729.

Merker M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Brändle M, Sigrist S, Amsler A, Pereira R, Bolliger R, Tribolet P, Braun N, Hoess C, Pavlicek V, Bilz S, Schuetz P. Vitamin D deficiency is highly prevalent in malnourished inpatients and associated with higher mortality: A prospective cohort study. *Medicine (Baltimore)* 2019; 98:e18113.

Bischofberger-Baumann B, Ebert A, Hader C, Fournier J, Bilz S. [Interdisciplinary Management of Sellar Masses]. *Praxis (Bern 1994)* 2019; 108:599-608.

Schuetz P, Brändle M, Benz C, Henzen C, Mattmann S, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Sigrist S, Bilz S, Schmid S, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Tribolet P, Bregenzer T, Braun N, Hoess C, Pavlicek V, Mueller B. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. *Lancet* 2019; 393:2312-2321.

Zulewski H, Dettmer M, Minder A, Clerici T, Triponez F, Oertli D, Weidner S, Steinert H, Haldemann A, Christ E, Bilz S, Giovanella L, Komminoth P. Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. *Swiss Med Wkly* 2019; 149:w14700.

Schöb M, Müller P, Gerth Y, Korte W, Rickli H, Brändle M, Bärlocher A, Bilz S. [Diagnosis and Treatment of Familial Hypercholesterolemia]. *Praxis (Bern 1994)* 2018; 107:1345-1353.

Bilz S, Flückiger M, Meienberg F, Falconnier C, Keller U, Puder J. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. *PloS one* 2018; 13:e0202007.

Fenske W, Christ E, Henzen C, Fischli S, Tönjes A, Mueller B, Schopohl J, Flitsch J, Brabant G, Fassnacht M, Kroiss M, Malzahn U, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, Ribeiro-Oliveira A, Drescher T, Bilz S, Vogt D, Christ-Crain M. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. *N Engl J Med* 2018; 379:428-439.

Hornemann T, Baumgartner M, Christ E, Bilz S, Meienberg F, Jung H, Gautschi M, Cremonesi A, Zhakupova A, Hagenbuch N, Alecu I, Hochuli M. Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I - A link to metabolic control. *Mol Genet Metab* 2018; 125:73-78.

Quarella M, Walser D, Brändle M, Fournier J, Bilz S. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. *J Clin Endocrinol Metab* 2017; 102:1451-1453.

Tümer Z, Petris M, Zhu S, Mercer J, Bukrinski J, Bilz S, Baerlocher K, Horn N, Møller L. A 37-year-old Menkes disease patient-Residual ATP7A activity and early copper administration as key factors in beneficial treatment. *Clin Genet* 2017; 92:548-553.

Streuli R, Krull I, Brändle M, Kolb W, Stalla G, Theodoropoulou M, Enzler-Tschudy A, Bilz S. A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease. *Endocrinol Diabetes Metab Case Rep* 2017; 2017

Koster-Rusch A, Capraro J, Nagel W, Clerici T, Stöckli S, Forrer F, Brändle M, Bilz S. Bilaterale Halsschwellung bei einer jungen Frau. *Swiss Medical Forum* 2016; 16:253-255.

Grouzmann E, Fischli S, Henzen C, Zulewski H, Sigrist S, Drescher T, Brändle M, Bilz S, Matter M, Triponez F, Tschopp O, Abid K. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?. *PloS one* 2015; 10:e0125426.

Niederer-Wuest S, Stöckli S, Ess S, Haile S, Müller J, Oettli R, Clerici T, Bilz S, Brändle M, Förbs D, Jochum W, Broglio Däppen M. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. *Surgery* 2015; 157:119-25.

Seelig E, Bilz S, Keller U, Meienberg F, Christ-Crain M. Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness. *PloS one* 2013; 8:e72876.

Seelig E, Keller U, Klarhöfer M, Scheffler K, Brand S, Holsboer-Trachsler E, Hatzinger M, Bilz S. Neuroendocrine regulation and metabolism of glucose and lipids in primary chronic insomnia: a prospective case-control study. *PloS one* 2013; 8:e61780.

Grouzmann E, Brakch N, Buclin T, Zulewski H, Kim K, Henzen C, Triponez F, Herren A, Bilz S, Matter M, Abid K. Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma. *J Clin Endocrinol Metab* 2012; 97:2773-81.

Kreiner A, Neuwirth C, Bilz S. Weniger alltägliche Bauchschmerzen. *Schweiz Med Forum* 2011; 11:85-96.

Stienen M, Cadosch D, Bilz S, Hildebrandt G, Gautschi O. [Craniopharyngioma--a "geographical malignant" tumour]. *Praxis (Bern 1994)* 2010; 99:911-21.

Sutter R, Killer H, Bilz S, Baumgartner M, Ott H, Steck A, Renaud S. Cerebral edema and intracranial hypertension in an adult with maple syrup urine disease. *European journal of neurology : the official journal of the European Federation of Neurological Societies* 2009; 16:e45-6.

Morino K, Philbrick W, White M, Sebastian D, Samuel V, Nagai Y, Moore I, Reznick R, Tsigotis D, Sono S, Bilz S, Neschen S, Shulman G. Muscle-specific IRS-1 Ser->Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. *Diabetes* 2008; 57:2644-51.

Mettler J, Bategay E, Egelhof T, Oertli D, Zimmerli L, Bilz S. [Hypertension and hyperhidrosis. Pheochromocytoma]. *Praxis* 2008; 97:73-6.

Petersen K, Rothman D, Papademetris X, Kahn B, Zeman L, Befroy D, Cline G, Yonemitsu S, Solomon G, Bilz S, Savage D, Dufour S, Shulman G. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proceedings of the National Academy of Sciences of the United States of America* 2007; 104:12587-94.

Conen D, Melly L, Kaufmann C, Bilz S, Ammann P, Schaer B, Sticherling C, Müller B, Osswald S. Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. *Journal of the American College of Cardiology* 2007; 49:2350-5.

Puder J, Varga S, Nusbaumer C, Zulewski H, Bilz S, Müller B, Keller U. Women with polycystic ovary syndrome are sensitive to the TNF-alpha-lowering effect of glucose-induced hyperinsulinaemia. *European journal of clinical investigation* 2006; 36:883-9.

Walter M, Wild D, Rasch H, Müller-Brand J, Müller B, Bilz S. Coregistered iodine-131 single photon emission computed tomography/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma. *Thyroid : official journal of the American Thyroid Association* 2006; 16:1063-4.

Christ-Crain M, Müller B, Bergmann A, Struck J, Korbonits M, Bilz S, Morgenthaler N, Ernst A, Stoeckli R, Keller U. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. *The Journal of clinical endocrinology and metabolism* 2006; 91:3544-7.

Bilz S, Samuel V, Morino K, Savage D, Choi C, Shulman G. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. *American journal of physiology. Endocrinology and metabolism* 2006; 290:E716-22.

Morino K, Pypaert M, Sono S, Bilz S, White M, Neschen S, Shatzkes N, Frattini J, Befroy D, Dufour S, Petersen K, Shulman G. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. *The Journal of clinical investigation* 2005; 115:3587-93.

Samuel V, Liu Z, Qu X, Elder B, Bilz S, Befroy D, Romanelli A, Shulman G. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *The Journal of biological chemistry* 2004; 279:32345-53.

von Mach M, Stoeckli R, Bilz S, Kraenzlin M, Langer I, Keller U. Changes in bone mineral content after surgical treatment of morbid obesity. *Metabolism: clinical and experimental* 2004; 53:918-21.

Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. *Journal of lipid research* 2004; 45:174-85.

Keller U, Szinnai G, Bilz S, Berneis K. Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. *European journal of clinical nutrition* 2003; 57 Suppl 2:S69-74.

Keller U, Turkalj I, Laager R, Bloesch D, Bilz S. Effects of medium- and long-chain fatty acids on whole body leucine and glucose kinetics in man. *Metabolism: clinical and experimental* 2002; 51:754-60.

Berneis K, Battegay M, Bassetti S, Nuesch R, Leisibach A, Bilz S, Keller U. Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients. *European journal of clinical investigation* 2000; 30:87-94.

Heim S, De Geyter C, Siegrist W, Bilz S, Keller U. [Polycystic ovary syndrome--only relevant in reproductive medicine?]. *Therapeutische Umschau. Revue thérapeutique* 1999; 56:271-5.

Bilz S, Ninnis R, Keller U. Effects of hypoosmolality on whole-body lipolysis in man. *Metabolism: clinical and experimental* 1999; 48:472-6.

Projekte (45)

Prevalence and screening of NAFLD and fibrosis in type 2 diabetes - a SwissDiab study

Klinische Forschung - 01.07.2023 - 31.10.2024

Automatisch geschlossen

OCEAN

Klinische Forschung - 01.05.2023 - 31.12.2024

Abgebrochen

VICTORION Real

Klinische Forschung - 01.11.2022 - 31.03.2027

Laufend

AMGEN202100057

Klinische Forschung - 01.05.2022 - 31.03.2023

Abgeschlossen

CAHmelia SPR001-203

Klinische Forschung - 01.12.2021 - 31.12.2025

Laufend

CAHmelia SPR001-204

Klinische Forschung - 01.12.2021 - 31.12.2025

Laufend

ACRODAT

Klinische Forschung - 01.12.2021 - 31.12.2025

Abgebrochen

Diabetescoach

Klinische Forschung - 01.04.2021 - 31.12.2030

Laufend

HIT-Studie

Klinische Forschung - 01.02.2021 - 31.12.2025

Laufend

ESSENCE

Klinische Forschung - 01.01.2021 - 31.12.2026

Laufend

ASSESS

Klinische Forschung - 01.12.2020 - 31.12.2021

Abgebrochen

COMET-T

Klinische Forschung - 01.12.2020 - 01.03.2022

Automatisch geschlossen

XLH-Register

Klinische Forschung - 01.12.2020 - 31.12.2030

Laufend

PIONEER REAL

Klinische Forschung - 01.09.2020 - 01.09.2022

Automatisch geschlossen

TRIAGE

Klinische Forschung - 01.09.2020 - 31.08.2021

Automatisch geschlossen

ESSENCE Study

Klinische Forschung - 01.08.2020 - 31.12.2029

Laufend

SANTORINI

Klinische Forschung - 01.07.2020 - 30.06.2022

Automatisch geschlossen

PHPT/ FHH-Studie

Klinische Forschung - 01.07.2020 - 31.12.2024

Laufend

Swiss Multicenter Randomized Controlled Trial on different Limb Lengths in Gastric Bypass Surgery

Klinische Forschung - 01.03.2020 - 28.02.2027

Laufend

Akromegalie-Register

Klinische Forschung - 06.09.2019 - 31.12.2029

Laufend

The role of physical activity, malnutrition and sarcopenia for the prediction of acute exacerbations and the evolution of COPD assessment test (CAT) in patients with COPD

Klinische Forschung - 29.11.2018 - 30.06.2021

Abgeschlossen

STEP 4

Klinische Forschung - 05.06.2018 - 31.05.2020

Abgeschlossen

Neuropeptide Y NPY-Trial bei Phäochromozytom

Klinische Forschung - 01.01.2018 - 01.01.2022

Abgeschlossen

PIONEER 7

Klinische Forschung - 08.12.2017 - 31.07.2019

Abgeschlossen

ECARA

Klinische Forschung - 01.09.2017 - 31.12.2018

Abgeschlossen

Swiss Pituitary Registry

Klinische Forschung - 01.06.2017 - 01.06.2021

Automatisch geschlossen

Schilddrüsenknoten-Register

Klinische Forschung - 01.03.2017 - 01.03.2021

Automatisch geschlossen

FIDELIO

Klinische Forschung - 01.12.2016 - 31.08.2020

Abgeschlossen

FERINJECT

Klinische Forschung - 01.11.2016 - 01.07.2018

Abgeschlossen

FIGARO-DKD

Klinische Forschung - 01.06.2016 - 31.03.2021

Abgeschlossen

APPRISE

Klinische Forschung - 16.03.2016 - 01.07.2018

Abgeschlossen

Spire 1022

Klinische Forschung - 01.01.2016 - 31.08.2017

Abgebrochen

Spire 1038

Klinische Forschung - 01.01.2016 - 31.08.2018

Abgebrochen

TOUJEO I

Klinische Forschung - 01.01.2016 - 01.01.2020

Abgeschlossen

CODDI

Klinische Forschung - 01.01.2016 - 31.10.2017

Abgeschlossen

EFFORT

Klinische Forschung - 01.01.2016 - 01.01.2020

Abgeschlossen

LX4211 310

Klinische Forschung - 10.10.2015 - 31.12.2017

Abgeschlossen

SUSTAIN

Klinische Forschung - 01.12.2013 - 31.01.2015

Abgeschlossen

SENECA - PILOT

Klinische Forschung - 27.08.2013 - 05.02.2014

Abgeschlossen

Sekretion von Katecholaminen und ihrer methoxylierten Metabolite durch die menschliche Nebenniere und durch Phäochromozytome

Klinische Forschung - 30.05.2013 - 31.12.2020

Automatisch geschlossen

The significance of Defensin alpha 4 in the pathophysiology of the adrenal insufficiency in inflammatory lung diseases

Grundlagenforschung - 01.09.2012 - 01.09.2013

Abgebrochen

DUAL II

Klinische Forschung - 24.12.2011 - 24.11.2012

Abgeschlossen

FAPAS Studie

Klinische Forschung - 15.12.2011 - 31.12.2013

Abgeschlossen

Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multinational trial with stratification of subject to either 56 or 160 weeks of treatment based on pre-diabetes status at randomisation

Klinische Forschung - 01.08.2011 - 31.07.2014

Automatisch geschlossen

Molecular and mutational profiling in Papillary Thyroid Carcinoma with special emphasis on the influence of BRAFV600E Mutation on Tumor Stage, Outcome and nuclear imaging

Klinische Forschung - 21.01.2011 - 30.12.2013

Abgeschlossen